2025
826 Analysis of National Burn Repository: Impact of Dermal Templates in Burn Management 2008 to 2021
Crombie R, Witherel C. 826 Analysis of National Burn Repository: Impact of Dermal Templates in Burn Management 2008 to 2021. Journal Of Burn Care & Research 2025, 46: s275-s275. PMCID: PMC11958102, DOI: 10.1093/jbcr/iraf019.357.Peer-Reviewed Original ResearchDermal templateNational Burn RepositoryAssociated with fewer infectionsHealth economic implicationsBurn RepositoryPatient demographic informationThird-degree burnsThermal burn injuryDermal regeneration templateEmergency room visitsNormal patientsBurn patientsFewer infectionsPatientsImprove outcomesClinical performanceRegistry dataOutcome measuresBurn injuryCost of careCare algorithmTBSARoom visitsRegeneration templateBurn management837 Impact of Autologous, Non-Autologous, Synthetic Tissue Substitutes in Burns 2016-2021: Analysis of National Burn Repository
Crombie R, Witherel C. 837 Impact of Autologous, Non-Autologous, Synthetic Tissue Substitutes in Burns 2016-2021: Analysis of National Burn Repository. Journal Of Burn Care & Research 2025, 46: s282-s282. PMCID: PMC11958335, DOI: 10.1093/jbcr/iraf019.368.Peer-Reviewed Original ResearchNon-autologousLong-term safetyHealth economic implicationsBurn careClinical benefitPatient cohortTissue substituteClinical studiesBurn patientsICD-10 codesNational Burn RepositoryPatientsThermal injuryCare algorithmInvestigated groupsBurn RepositoryICD-10Procedure codesTissueImpact of cAMPSkin substitutes
2024
Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia
Bewersdorf J, Patel K, Shallis R, Podoltsev N, Kewan T, Stempel J, Mendez L, Stahl M, Stein E, Huntington S, Goshua G, Zeidan A. Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia. Leukemia & Lymphoma 2024, 65: 1136-1144. PMID: 38648559, PMCID: PMC11265977, DOI: 10.1080/10428194.2024.2344052.Peer-Reviewed Original ResearchQuality-adjusted life yearsCompletion of consolidation therapyFLT3-mutant acute myeloid leukemiaAllogeneic hematopoietic cell transplantationIncremental cost-effectiveness ratioProbabilistic sensitivity analysesImproved overall survivalHematopoietic cell transplantationPartitioned survival analysis modelAcute myeloid leukemiaCost-effectiveness ratioFLT3 inhibitor quizartinibHealth economic implicationsConsolidation therapyInduction chemotherapyAverage wholesale priceOverall survivalCell transplantationContinuous therapyMyeloid leukemiaITD mutationQuizartinibIncremental costCost-effective optionLife years87 Impact of Skin Substitute Use for Burns: An Analysis of the ABA National Burn Repository
Crombie R, Witherel C. 87 Impact of Skin Substitute Use for Burns: An Analysis of the ABA National Burn Repository. Journal Of Burn Care & Research 2024, 45: 69-70. PMCID: PMC11023360, DOI: 10.1093/jbcr/irae036.086.Peer-Reviewed Original ResearchLength of stayOutcome measuresLong-term safetySkin substitutesDay of admissionHealth economic implicationsDepth of burnInsufficient autograftManagement of thermal injuriesSubstitution patientsSurviving patientsPatient demographicsPatient cohortInhalation injuryNormal patientsICD-10 codesSize burnsTBSA burnSubstitute useBurn sizePatientsNational Burn RepositoryThermal injuryRegenerative graftsICD-9
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply